This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Gemoscan Canada, Inc. Announces Proposed Acquisition And Financing

TORONTO, July 15, 2013 (GLOBE NEWSWIRE) -- Gemoscan Canada, Inc. ("Gemoscan" or the "Corporation") – (TSX-V:GES) (MUN:1GE) wishes to announce that it has made an offer to acquire a 100% interest in Physiomed Kennedy Inc. ("PKI"), which operates a paramedical clinic in Toronto, Ontario (the "Acquisition"). The purchase price has been negotiated on the basis of a multiple of PKI's normalized earnings before interest, tax, depreciation and amortization ("EBITDA") as at April 30, 2013 and is subject to adjustment based on results as of April 30, 2014. The consideration is to be paid as to 43.75% cash, 37.5% pursuant to a debenture issued to the vendor (the "VTB") and 18.75% in shares of Gemoscan priced upon the closing of the Acquisition. The VTB shall bear interest at the rate of 8% per annum and shall have a term of 24 months from the closing of the Acquisition. Interest shall be paid monthly but no principal payments are required until the due date. 

Completion of the Acquisition is conditional on completion of financing, the negotiation of a definitive agreement between the parties and the receipt of all applicable regulatory approvals including the approval of the TSX Venture Exchange.

Through a combination of organic growth and strategic acquisitions Gemoscan is following through on its plans to emerge as a leading platform in the quickly emerging retail based health and wellness sector.

The acquisition of PKI will be one the stepping-stones intended to drive incremental sales and profitability for the Company. The acquisition of PKI and similar businesses in the future is expected to be immediately accretive to Gemoscan while presenting the Company with a captive distribution channel through which to sell its current core offerings.

Scott Wilson, a director of Gemoscan, owns 50% of PKI through a related company. As a result, the Acquisition is a related party transaction as such term is defined in Multilateral Instrument 61-101 – Protection of Minority Security Holders in Special Transactions ("MI 61-101"). The Acquisition is exempt from the valuation and minority shareholder approval requirements of MI 61-101 by reason of the exemptions contained in sections 5.5(a) and 5.7(1)(a) as the total consideration being received by Mr. Wilson does not exceed 25% of Gemoscan's market capitalization.


The Corporation and NorthStar Bancorp Limited ("Northstar") have executed a binding term sheet to provide up to $1,500,000 in secured convertible debentures (the "Debentures"). The Debentures would be provided further to the Corporation's press release dated March 18, 2013 pursuant to which it announced it had entered into a financing facilitation agreement with Northstar, whereby Northstar would provide up to $10,000,000 in financing. The Debentures will bear interest at the rate of 10.75% per annum and will have a term of 2 years. Interest only shall be payable during the term with the principal due on the due date. The Debentures will be convertible in the first year at the greater of $0.20 and the 20 day average closing price less a 15% discount at the time a notice of conversion is given. In the second year, the minimum exercise price shall increase to $0.30. The Debentures will be secured against the assets of the Corporation and PKI upon the completion of the Acquisition. The use of proceeds for the Debentures shall be as follows: (i) to repay all outstanding secured debt of the Corporation; (ii) to fund the cash portion of the purchase price for the Acquisition; and (iii) for working capital. Phoenix Capital Partners Inc. ("Phoenix") acted as the exclusive advisors for Gemoscan in arranging the Debenture financing.

1 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
AAPL $95.03 -2.90%
FB $116.73 7.20%
GOOG $691.02 -2.10%
TSLA $247.54 -1.60%
YHOO $36.59 -0.97%


Chart of I:DJI
DOW 17,830.76 -210.79 -1.17%
S&P 500 2,075.81 -19.34 -0.92%
NASDAQ 4,805.2910 -57.85 -1.19%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs